keyword
https://read.qxmd.com/read/38687384/endobronchial-ultrasound-guided-transbronchial-needle-aspiration-and-next-generation-sequencing-yields
#1
JOURNAL ARTICLE
Kristin N Sheehan, Lara M Khoury, Angela G Niehaus, William I Mariencheck, Katherine A Gershner, Travis L Dotson, Christina R Bellinger
PURPOSE: The use of endobronchial ultrasound (EBUS) is standard practice for lung cancer diagnosis and staging. Next generation sequencing (NGS) for detection of genetic alterations is recommended in advanced, non-squamous, non-small-cell lung cancer (NSCLC). Existing protocols for NGS testing are minimal and reported yields vary. This study aimed to determine the yield of EBUS samples obtained for NGS using a sampling protocol at our institution and assess predictive factors to form collection protocols...
April 30, 2024: Lung
https://read.qxmd.com/read/38686933/multicenter-prospective-trial-of-non-endoscopic-biomarker-driven-detection-of-barrett-s-esophagus-and-esophageal-adenocarcinoma
#2
JOURNAL ARTICLE
Helen R Moinova, Suman Verma, John Dumot, Ashley Faulx, Prasad G Iyer, Marcia Irene Canto, Jean S Wang, Nicholas J Shaheen, Prashanthi N Thota, Lishan Aklog, Joseph E Willis, Sanford D Markowitz, Amitabh Chak
BACKGROUND: Preliminary data suggest that an encapsulated balloon (EsoCheckTM), coupled with a two methylated DNA biomarker panel (EsoGuardTM), detects Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) with high accuracy. The initial assay required sample freezing upon collection. AIM: Assess a next-generation EsoCheck sampling device and EsoGuard assay in a much-enlarged multicenter study clinically enhanced by utilizing a CLIA-compliant assay and samples maintained at room temperature...
April 30, 2024: American Journal of Gastroenterology
https://read.qxmd.com/read/38685149/early-evaluation-of-circulating-tumor-dna-as-marker-of-therapeutic-efficacy-and-prognosis-in-breast-cancer-patients-during-primary-systemic-therapy
#3
JOURNAL ARTICLE
Ru Wang, Bin Wang, Huimin Zhang, Xiaoqin Liao, Bohui Shi, Yuhui Zhou, Can Zhou, Yu Yan, Wei Zhang, Ke Wang, Guanqun Ge, Yu Ren, Xiaojiang Tang, Baoyu Gan, Jianjun He, Ligang Niu
BACKGROUND: We assessed the potential role of serial circulating tumor DNA (ctDNA) as a biomarker to monitor treatment response to primary systemic therapy (PST) in breast cancer and evaluated the predictive value of ctDNA to further identify patients with residual disease. METHODS: We prospectively enrolled 208 plasma samples collected at three time points (before PST, after 2 cycles of treatment, before surgery) of 72 patients with stage Ⅱ-III breast cancer...
April 24, 2024: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/38684670/the-genomic-profiling-of-high-risk-smoldering-myeloma-patients-treated-with-an-intensive-strategy-unveils-potential-markers-of-resistance-and-progression
#4
JOURNAL ARTICLE
A Medina-Herrera, I Vazquez, I Cuenca, J M Rosa-Rosa, B Ariceta, C Jimenez, M Fernandez-Mercado, M J Larrayoz, N C Gutierrez, M Fernandez-Guijarro, V Gonzalez-Calle, P Rodriguez-Otero, A Oriol, L Rosiñol, A Alegre, F Escalante, J De La Rubia, A I Teruel, F De Arriba, M T Hernandez, J Lopez-Jimenez, E M Ocio, N Puig, B Paiva, J J Lahuerta, J Bladé, J F San Miguel, M V Mateos, J Martinez-Lopez, M J Calasanz, R Garcia-Sanz
Smoldering multiple myeloma (SMM) precedes multiple myeloma (MM). The risk of progression of SMM patients is not uniform, thus different progression-risk models have been developed, although they are mainly based on clinical parameters. Recently, genomic predictors of progression have been defined for untreated SMM. However, the usefulness of such markers in the context of clinical trials evaluating upfront treatment in high-risk SMM (HR SMM) has not been explored yet, precluding the identification of baseline genomic alterations leading to drug resistance...
April 29, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38684052/design-and-evaluation-of-a-robust-crispr-kinetic-assay-for-hot-spot-genotyping
#5
JOURNAL ARTICLE
Charles Blanluet, Calvin J Kuo, Asmita Bhattacharya, Juan G Santiago
Next-generation sequencing offers highly multiplexed and accurate detection of nucleic acid sequences but at the expense of complex workflows and high input requirements. The ease of use of CRISPR-Cas12 assays is attractive and may enable highly accurate detection of sequences implicated in, for example, cancer pathogenic variants. CRISPR assays often employ end-point measurements of Cas12 trans-cleavage activity after Cas12 activation by the target; however, end point-based methods can be limited in accuracy and robustness by arbitrary experimental choices...
April 29, 2024: Analytical Chemistry
https://read.qxmd.com/read/38680177/composition-of-the-sputum-bacterial-microbiome-of-patients-with-different-pathomorphological-forms-of-non-small-cell-lung-cancer
#6
JOURNAL ARTICLE
V G Druzhinin, E D Baranova, P S Demenkov, L V Matskova, A V Larionov
Recent studies have shown that the bacterial microbiome of the respiratory tract influences the development of lung cancer. Changes in the composition of the microbiome are observed in patients with chronic inflammatory processes. Such microbiome changes may include the occurrence of bacteria that cause oxidative stress and that are capable of causing genome damage in the cells of the host organism directly and indirectly. To date, the composition of the respiratory microbiome in patients with various histological variants of lung cancer has not been studied...
April 2024: Vavilovskii Zhurnal Genetiki i Selektsii
https://read.qxmd.com/read/38679207/plasmacytoid-urothelial-carcinoma-of-the-urinary-bladder-a-clinicopathological-and-molecular-analysis-of-52-cases
#7
JOURNAL ARTICLE
Lan Zheng, Hui Chen, Jianping Zhao, Sinchita Roy-Chowdhuri, Ashish M Kamat, Omar Alhalabi, Jianjun Gao, Arlene Siefker-Radtke, Donna E Hansel, Bogdan Czerniak, Charles C Guo
Plasmacytoid urothelial carcinoma (UC) is a rare histologic subtype of bladder cancer that is associated with an aggressive clinical behavior. We analyzed the clinicopathologic and molecular features of plasmacytoid UC in 52 patients from a single institute. The patients included 44 men and 8 women, with a mean age of 64 years (range, 41-91 years). All bladder cancers were high-grade UC, and plasmacytoid component accounted for a mean of 47% of bladder tumors (range, 5-100%). Distinct gene mutations were found in most plasmacytoid UCs (n=49); the most common mutations were TP53 (n=30), followed by TERT (n=20), and CDH1 (n=18)...
April 26, 2024: Human Pathology
https://read.qxmd.com/read/38677768/dna-checkpoint-gene-mutation-as-a-biomarker-for-immune-checkpoint-inhibitor-therapy-in-advanced-biliary-tract-cancer
#8
JOURNAL ARTICLE
Ji Eun Shin, Seung Tae Kim
BACKGROUND/AIM: The DNA checkpoint (DNACHK) pathway is engaged in signaling the need for cell cycle arrest. This pathway is being actively researched to assess its role in cancer immunotherapy. PATIENTS AND METHODS: A total of 62 patients participated in this study. These patients were treated with immune checkpoint inhibitors (ICIs) for advanced biliary tract cancers (BTCs) from March 2020 to August 2022 at Samsung Medical Center. DNACHK mutated were defined as genomic alterations, such as single nucleotide variants, multi-nucleotide variants, and short insertion and deletions in seven genes; checkpoint kinase 1 (CHEK1), checkpoint kinase 2 (CHEK2), BRCA1, DNA repair-associated (BRCA1), the serine/threonine kinase ATM, the serine/threonine kinase ATR, mediator of DNA damage checkpoint 1 (MDC1) and tumor protein p53 binding protein 1 (TP53BP1)...
May 2024: Anticancer Research
https://read.qxmd.com/read/38677762/genetic-and-immunological-characterization-of-brain-metastases-from-solid-cancers
#9
JOURNAL ARTICLE
Shoichi Deguchi, Yasuto Akiyama, Koichi Mitsuya, Tomoatsu Ikeya, Chikako Hozumi, Akira Iizuka, Haruo Miyata, Chie Maeda, Tadashi Ashizawa, Takeshi Nagashima, Kenichi Urakami, Keiichi Ohshima, Koji Muramatsu, Takashi Sugino, Yasuhisa Ohde, Yasuhiro Tsubosa, Seiichiro Nishimura, Ken Yamaguchi
BACKGROUND/AIM: Brain metastasis, a leading cause of cancer death, is a clinical challenge. Recently, genetic characterization of brain metastatic lesions based on next generation sequencing-based advanced technologies, such as single-cell RNA sequencing, has been performed to develop novel efficient therapies. The present study aimed to investigate brain-metastasis-specific biomarkers as well as relevant prognostic factors. PATIENTS AND METHODS: The genetic profiles and expression levels of immune response-associated genes and 820 cancer-associated genes were compared between primary cancer lesions and metastatic cancer lesions obtained from nine cancer patients at the Shizuoka Cancer Center...
May 2024: Anticancer Research
https://read.qxmd.com/read/38677541/from-biology-to-personalized-medicine-recent-knowledge-in-osteosarcoma
#10
JOURNAL ARTICLE
Audrey Mohr, Maria Eugenia Marques Da Costa, Olivia Fromigue, Baptiste Audinot, Thierno Balde, Robin Droit, Samuel Abbou, Pierre Khneisser, Pablo Berlanga, Esperanza Perez, Antonin Marchais, Nathalie Gaspar
High-grade osteosarcoma is the most common paediatric bone cancer. More than one third of patients relapse and die of osteosarcoma using current chemotherapeutic and surgical strategies. To improve outcomes in osteosarcoma, two crucial challenges need to be tackled: 1-the identification of hard-to-treat disease, ideally from diagnosis; 2- choosing the best combined or novel therapies to eradicate tumor cells which are resistant to current therapies leading to disease dissemination and metastasize as well as their favorable microenvironment...
April 25, 2024: European Journal of Medical Genetics
https://read.qxmd.com/read/38676371/strategic-approaches-in-oral-squamous-cell-carcinoma-diagnostics-using-liquid-biopsy
#11
REVIEW
Denis F Kinane, Joerg Gabert, George Xynopoulos, Esra Guzeldemir-Akcakanat
Liquid biopsy is a noninvasive diagnostic technique used for monitoring cancer utilizing specific genetic biomarkers present in bodily fluids, such as blood, saliva, or urine. These analyses employ multiple biomolecular sources including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes (that contain DNA fragments) to detect genetic biomarkers that can predict, disclose, and/or monitor cancers. Levels of these biomarkers can inform on the presence of cancer, its genetic characteristics, and its potential treatment response and also provide predictive genetic predisposition information for specific cancers including oral squamous cell carcinomas (OSCC)...
April 27, 2024: Periodontology 2000
https://read.qxmd.com/read/38675937/combining-cellular-immunization-and-phage-display-screening-results-in-novel-fc%C3%AE-ri-specific-antibodies
#12
JOURNAL ARTICLE
Steffen Krohn, Tosca Holtrop, Arianne M Brandsma, Petra Moerer, Maaike Nederend, Nikos Darzentas, Monika Brüggemann, Katja Klausz, Jeanette H W Leusen, Matthias Peipp
Antibodies that specifically bind to individual human fragment crystallizable γ receptors (FcγRs) are of interest as research tools in studying immune cell functions, as well as components in bispecific antibodies for immune cell engagement in cancer therapy. Monoclonal antibodies for human low-affinity FcγRs have been successfully generated by hybridoma technology and are widely used in pre-clinical research. However, the generation of monoclonal antibodies by hybridoma technology that specifically bind to the high-affinity receptor FcγRI is challenging...
April 12, 2024: Viruses
https://read.qxmd.com/read/38675779/case-report-long-term-survival-of-a-patient-with-cerebral-metastasized-ovarian-carcinoma-treated-with-a-personalized-peptide-vaccine-and-anti-pd-1-therapy
#13
Henning Zelba, Christina Kyzirakos, Simone Kayser, Borong Shao, Annekathrin Reinhardt, Natalia Pieper, Armin Rabsteyn, Dennis Döcker, Sorin Armeanu-Ebinger, Matthias Kloor, Dirk Hadaschik, Martin Schulze, Florian Battke, Alexander Golf, Saskia Biskup
Ovarian cancer is one of the most common cancers among women and the most lethal malignancy of all gynecological cancers. Surgery is promising in the early stages; however, most patients are first diagnosed in the advanced stages, where treatment options are limited. Here, we present a 49-year-old patient who was first diagnosed with stage III ovarian cancer. After the tumor progressed several times under guideline therapies with no more treatment options available at that time, the patient received a fully individualized neoantigen-derived peptide vaccine in the setting of an individual healing attempt...
April 9, 2024: Vaccines
https://read.qxmd.com/read/38674331/comprehensive-analysis-of-clinically-relevant-copy-number-alterations-cnas-using-a-523-gene-next-generation-sequencing-panel-and-nxclinical-software-in-solid-tumors
#14
JOURNAL ARTICLE
Vivek Gupta, Vishakha Vashisht, Ashutosh Vashisht, Ashis K Mondal, Ahmet Alptekin, Harmanpreet Singh, Ravindra Kolhe
Copy number alterations (CNAs) are significant in tumor initiation and progression. Identifying these aberrations is crucial for targeted therapies and personalized cancer diagnostics. Next-generation sequencing (NGS) methods present advantages in scalability and cost-effectiveness, surpassing limitations associated with reference assemblies and probe capacities in traditional laboratory approaches. This retrospective study evaluated CNAs in 50 FFPE tumor samples (breast cancer, ovarian carcinoma, pancreatic cancer, melanoma, and prostate carcinoma) using Illumina's TruSight Oncology 500 (TSO500) and the Affymetrix Oncoscan Molecular Inversion Probe (OS-MIP) (ThermoFisher Scientific, Waltham, MA, USA)...
March 23, 2024: Genes
https://read.qxmd.com/read/38674014/gut-bacteria-provide-genetic-and-molecular-reporter-systems-to-identify-specific-diseases
#15
REVIEW
Leon M T Dicks
With genetic information gained from next-generation sequencing (NGS) and genome-wide association studies (GWAS), it is now possible to select for genes that encode reporter molecules that may be used to detect abnormalities such as alcohol-related liver disease (ARLD), cancer, cognitive impairment, multiple sclerosis (MS), diabesity, and ischemic stroke (IS). This, however, requires a thorough understanding of the gut-brain axis (GBA), the effect diets have on the selection of gut microbiota, conditions that influence the expression of microbial genes, and human physiology...
April 17, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38673836/error-corrected-deep-targeted-sequencing-of-circulating-cell-free-dna-from-colorectal-cancer-patients-for-sensitive-detection-of-circulating-tumor-dna
#16
JOURNAL ARTICLE
Amanda Frydendahl, Mads Heilskov Rasmussen, Sarah Østrup Jensen, Tenna Vesterman Henriksen, Christina Demuth, Mathilde Diekema, Henrik Jørn Ditzel, Sara Witting Christensen Wen, Jakob Skou Pedersen, Lars Dyrskjøt, Claus Lindbjerg Andersen
Circulating tumor DNA (ctDNA) is a promising biomarker, reflecting the presence of tumor cells. Sequencing-based detection of ctDNA at low tumor fractions is challenging due to the crude error rate of sequencing. To mitigate this challenge, we developed ultra-deep mutation-integrated sequencing (UMIseq), a fixed-panel deep targeted sequencing approach, which is universally applicable to all colorectal cancer (CRC) patients. UMIseq features UMI-mediated error correction, the exclusion of mutations related to clonal hematopoiesis, a panel of normal samples for error modeling, and signal integration from single-nucleotide variations, insertions, deletions, and phased mutations...
April 11, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38672677/correlation-of-molecular-status-with-preoperative-olfactory-function-in-olfactory-groove-meningioma
#17
JOURNAL ARTICLE
Dino Podlesek, Friederike Beyer, Majd Alkhatib, Dirk Daubner, Mido Max Hijazi, Jerry Hadi Juratli, Susanne Weise, Ilker Y Eyüpoglu, Gabriele Schackert, Tareq A Juratli, Thomas Hummel
PURPOSE: The study aims to examine the possible correlation between genomic alterations and preoperative olfactory function in patients with olfactory groove meningioma (OGM), due to the frequent presence of olfactory impairment. METHODS: We utilised next-generation sequencing to analyse samples from 22 individuals with OGM in order to detect driver mutations. Tumour morphology was assessed using preoperative imaging, whereas olfactory function was examined using Sniffin' Sticks...
April 22, 2024: Cancers
https://read.qxmd.com/read/38672670/trna-derived-fragments-as-biomarkers-in-bladder-cancer
#18
JOURNAL ARTICLE
Olaf Strømme, Kathleen A Heck, Gaute Brede, Håvard T Lindholm, Marit Otterlei, Carl-Jørgen Arum
Bladder cancer (BC) diagnosis is reliant on cystoscopy, an invasive procedure associated with urinary tract infections. This has sparked interest in identifying noninvasive biomarkers in body fluids such as blood and urine. A source of biomarkers in these biofluids are extracellular vesicles (EVs), nanosized vesicles that contain a wide array of molecular cargo, including small noncoding RNA such as transfer RNA-derived fragments (tRF) and microRNA. Here, we performed small-RNA next-generation sequencing from EVs from urine and serum, as well as from serum supernatant...
April 20, 2024: Cancers
https://read.qxmd.com/read/38672657/genetic-diagnosis-of-retinoblastoma-using-aqueous-humour-findings-from-an-extended-cohort
#19
JOURNAL ARTICLE
Amy Gerrish, Chipo Mashayamombe-Wolfgarten, Edward Stone, Claudia Román-Montañana, Joseph Abbott, Helen Jenkinson, Gerard Millen, Sam Gurney, Maureen McCalla, Sarah-Jane Staveley, Anu Kainth, Maria Kirk, Claire Bowen, Susan Cavanagh, Sancha Bunstone, Megan Carney, Ajay Mohite, Samuel Clokie, M Ashwin Reddy, Alison Foster, Stephanie Allen, Manoj Parulekar, Trevor Cole
The identification of somatic RB1 variation is crucial to confirm the heritability of retinoblastoma. We and others have previously shown that, when tumour DNA is unavailable, cell-free DNA (cfDNA) derived from aqueous humour (AH) can be used to identify somatic RB1 pathogenic variation. Here we report RB1 pathogenic variant detection, as well as cfDNA concentration in an extended cohort of 75 AH samples from 68 patients. We show cfDNA concentration is highly variable and significantly correlated with the collection point of the AH...
April 19, 2024: Cancers
https://read.qxmd.com/read/38672643/ngs-guided-precision-oncology-in-breast-cancer-and-gynecological-tumors-a-retrospective-molecular-tumor-board-analysis
#20
JOURNAL ARTICLE
Niklas Gremke, Fiona R Rodepeter, Julia Teply-Szymanski, Sebastian Griewing, Jelena Boekhoff, Alina Stroh, Thomas S Tarawneh, Jorge Riera-Knorrenschild, Christina Balser, Akira Hattesohl, Martin Middeke, Petra Ross, Anne-Sophie Litmeyer, Marcel Romey, Thorsten Stiewe, Thomas Wündisch, Andreas Neubauer, Carsten Denkert, Uwe Wagner, Elisabeth K M Mack
Background: Precision oncology treatments are being applied more commonly in breast and gynecological oncology through the implementation of Molecular Tumor Boards (MTBs), but real-world clinical outcome data remain limited. Methods: A retrospective analysis was conducted in patients with breast cancer (BC) and gynecological malignancies referred to our center's MTB from 2018 to 2023. The analysis covered patient characteristics, next-generation sequencing (NGS) results, MTB recommendations, therapy received, and clinical outcomes...
April 19, 2024: Cancers
keyword
keyword
164447
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.